Drug companies face Medicare price negotiation deadline

SKIN
Tags :
SKIN
Share This :


The Centers for Medicare and Medicaid Services (CMS) set an Oct. 1 deadline for companies to either agree to bargain with the federal government over pricing or face penalties.

 

Given the two options available to those who decide against bargaining — a heavy excise tax or withdrawing all their products from Medicare and Medicaid coverage — some have already said they plan to sign agreements, even though they are suing to stop it.

 

“We remain committed to ensuring patients have access to FARXIGA and plan to participate in the process outlined by CMS to communicate the value of FARXIGA to people covered by Medicare,” a spokesperson for AstraZeneca said.

 

Merck said it would be signing the agreement “under protest.”

 

“Withdrawing all of the company’s products from Medicare and Medicaid would have devastating consequences for the millions of Americans who rely on our innovative medicines, and it is not tenable for any manufacturer to abandon nearly half of the U.S. prescription drug market,” said Merck.

 

A spokesperson for Bristol Myers Squibb similarly said the company has “no choice other than to sign the ‘agreement.’”


AstraZeneca’s diabetes drug Farxiga, Merck’s Type 2 diabetes drug Januvia and Bristol Myers Squibb’s Eliquis were among the first 10 drugs chosen by the Biden administration last month.

 

Others were more ambiguous on their plans.

 

Novo Nordisk said it would “continue to explore all options that allow us to drive change for people that need it and strive to continue to bring innovative medicines to the market while helping increase access for those that need them” when asked about its intentions.

 

There was a chance that the companies could have avoided negotiating for a little longer, but a ruling from a federal judge on Friday dashed any hopes of that happening.

 

The Chamber of Commerce, one of many groups suing to stop the program, had requested a preliminary injunction on the process by Oct. 1.

 

But U.S. District Judge Michael J. Newman found in his ruling on Friday that the organization had failed to prove that an injunction was necessary.

 

“They have demonstrated neither a strong likelihood of success nor irreparable harm. Consequently, their request for immediate preliminary injunctive relief—to stop implementation of the Program on or before October 1, 2023—is denied,” wrote Newman.

 

With this ruling in place, the Medicare negotiation program can go forward as planned.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Popular News Posts

Categories

Our Exclusive Products

Our Store

Our mission is simple, offer quality products that make our customers lives better at a reasonable price, while ensuring a hassle-free shopping experience. This means that before we bring a product to market, we test it to ensure that it meets our high-level quality standards. Our customer service team understand our products and can answer most every product related question quickly and efficiently. We strive everyday to meet and exceed our customers’ expectations of quality and support! Should we ever fail to meet this expectation – contact us and we will make it right!

Our Value: We are proud of our product and accomplishments, but we typically don’t shout it from the rooftop. Instead, we prefer to let our product and customers do the talking. Our core values can be recognized in our product. The qualities we strive for include:

Pragmatism: We design simple, useful solutions for common needs
Quality: From design to final product, we strive for durable solutions that work
Originality: Creativity and innovation are what makes our product unique
Design: Our minimalist and bold design language focuses on functionality and simplicity that is timeless

0 +

Top Rated Products

0 +

Happy Customers